POET Technologies {TSX.V: PTK} have filed MD & A documents for the six months ended 30th June 2015.

The board have also announced a revised “lab to fab” plan to commercialise their product range…..

NEWS RELEASE

POET Technologies files its Interim Financial Statements and MD&A for the 6 Months ended June 30, 2015.

Toronto, ON, San Jose, CA, and Storrs, CT, August 12, 2015 – POET Technologies Inc. {TSX-V: PTK} and {OTCQX: POETF} – developer of the planar opto-electronic technology (“POET”) platform for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single semiconductor wafer, wishes to announce that it has filed today its interim financial statements and MD&A for the six month period ended June 30, 2015.

The documents were approved by the Board of Directors (the “Board”) at its meeting
held on August 10, 2015. At the meeting, the directors were presented with reports from Dr. Suresh Venkatesan, the Company’s new Chief Executive Officer, and Dr. Subhash Deshmukh, the Company’s new Chief Operating Officer. They have been working extremely diligently since their recent appointment to develop a new plan in furtherance of the Company’s transition from lab-to-fab.

The directors were extremely pleased with the early positive progress reported by the new management team. As pointed out in the MD&A: “With an immediate view to commercialisation, the Company has continued to develop the base process technology necessary to build the complete suite of optoelectronics devices. The new management team is focused on exploiting existing high growth markets where the disruptive power of the POET platform IP provides competitive differentiation.”

 
POET initiates commercialization process of its differentiated technology The core source of technology differentiation has been validated in the laboratory at the University of Connecticut, and with that the Company is positioning itself to take its technology to the commercialization phase.

The Company has, for the first time, engaged commercial epitaxial wafer suppliers in providing wafers with the unique and proprietary POET epitaxial stack. While comprehensive discussions are underway with a number of potential foundry and epitaxial wafer partners, we have recently signed memorandums of understanding with some of these companies and expect to continue this process. This should accelerate the lab-fab transition, utilizing state of the art processes that position the Company for success in defined commercial markets.

“We are pleased to be working with well-established companies as both our foundry partners and as suppliers of our proprietary epitaxial wafers”, said Dr. Venkatesan. “We are focused on monetizing the technology in existing and proven high growth markets
where the disruptive technology innovations will provide a relevant and sustained source of competitive differentiation. We will be communicating the vision, objectives and accelerated drive to product realization around the end of September.”
Dr. Taylor’s revised role at POET Technologies to accelerate development of new technology and product applications Dr. Geoff Taylor, the Company’s Chief Scientist, has realigned his role in the Company. Dr. Taylor has resigned as a director and has entered into a new consulting contract to provide the Company with technical and analytic
support on the development of the POET integrated circuit technology platform and its initial products.
“I am thankful to the Board of Directors for its support. I am looking forward to concentrating on my primary mission, the uplifting of POET to a mainstream integrated circuit technology. To this end I will be providing technical input to the Board in the development and expansion of the POET IP platform”, said Dr. Taylor. “Our CEO, Dr. Venkatesan, has joined the Board and has provided new meaningful and exciting ideas for
the deployment of our technology. I will continue to advise the Board and liaise with Suresh on both technology improvement and implementation in new areas of focus. Both Suresh and I are increasingly convinced about the potential and applications of the disruptive POET platform as we set our sights towards commercialisation.”
“Transitioning Board responsibilities to Suresh, allows me to spend more time working on new technology and product applications.”
“Dr. Taylor’s innovations and keen insights that have culminated in the POET technology platform, promise to enable disruptions in cost and power over incumbent solutions. I would like to thank Geoff on behalf of the Board for his contributions over the years”, said Dr. Venkatesan. “I look forward to continuing to work with Geoff as we incorporate the technology into products. He will continue to be an active contributor to the development of the technology and products and will be the Chief Technical advisor to and prime source of innovation for the management team.”

About POET Technologies Inc.

POET Technologies is the developer of the POET platform for monolithic fabrication of integrated circuit devices  containing both electronic and optical elements on a single semiconductor wafer.

With head office in Toronto, Ontario, Canada, and operations in San Jose, CA and Storrs, CT, the Company, through ODIS Inc., a U.S. company, designs III-V semiconductor devices for military, industrial and commercial applications, including infrared sensor arrays and ultra-low-power random access memory. The Company has several issued and pending patents for the POET process, with potential high speed and power-efficient applications in devices such as servers, tablet computers and smartphones.

The Company’s common shares trade on the TSX Venture Exchange under the
symbol PTK.V.

For more information please visit our website at

www.poet-technologies.com

ON BEHALF OF THE BOARD OF DIRECTORS

Michel Lafrance, Secretary.
For further information:
Christopher Chu, Taylor Rafferty, LLC
Tel: +1 908 251 9869

Email: poet@taylor-rafferty.com

POET TECHNOLOGIES INC.
Head Office: Operations Office:
Suite 501, 121 Richmond St. W P.O. Box 555
Toronto, ON, Canada.

Phone: +1 416 368 9411

Fax:     +1 416 861 0749

M5H 2K1 Storrs-Mansfield, CT 06268

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the  TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release.

Kootenay Silver Inc. {TSX.V:  KTN} announced the closure of the first tranche of their private placement for just over $1 million.

This is a non brokered private placement.

VANCOUVER, Aug. 11, 2015 – Kootenay Silver Inc. { (TSX.V:  KTN} is pleased to announce that, further to its press release dated July 16, 2015, it has closed the initial tranche of its non-brokered private placement and issued an aggregate of 3,586,500 units (each a “Unit”) at a purchase price of $0.30 per Unit raising gross proceeds to the Company of $1,075,950.

The Company anticipates closing the balance of the Private Placement shortly and will provide an update in due course. 

Each unit consists of one common share and one transferable share purchase warrant  of Kootenay. Each Warrant entitles the holder to acquire one Common Share at an exercise price of $0.55 until August 10, 2017.   Upon approval by the TSX Venture Exchange, cash finder’s fees to arm’s length parties totaling $7,110 and the issuance of 96,000 finders units (the “Finders Units”), have been paid on this portion of the Private Placement.  The Finders Units consist of one Common Share and one non-transferable common share purchase Warrant. All securities issued in connection with the Private Placement are subject to a hold period which expires on December 11, 2015.

The net proceeds from the Private Placement will be used to finance additional work on Kootenay’s Promontorio property, which includes the new La Negra Breccia discovery, its other properties, and for general working capital purposes.

The securities being offered have not been, nor will they be registered under the United States Securities Act of 1933, as amended, or state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. federal and state registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale of securities in the United States.

La Negra Silver Discovery

The La Negra Breccia prospect is situated approx. 6.5 kms north of Kootenay’s Promontorio silver mineral resource property in Sonora, Mexico and is contained within a 25 x 15 km mineralised corridor, the ‘Promontorio Mineral Belt.’

Initial exploration on La Negra included a successful trenching and surface sampling program that confirmed extensive silver mineralisation over a large 100 to 200 meters by 500 meters area on surface. (See news releases from May 28th and June 5th, 2014 for more details). A follow up Phase I drill program on La Negra returned significant and consistent intervals of high grade, widespread silver mineralisation extending from surface to depth, confirming a substantial new silver discovery.

Results from a recent Phase II drilling program on La Negra have further confirmed the continuity of silver grades and the consistency of silver mineralisation to depth within the core of the diatreme breccia. (See news releases from March 31st, April 30th and May 20th, 2015 for more details). This has set the stage for the advanced future development of La Negra and reinforces its future potential as a low-cost, open pittable silver resource. At present, drill results from the program are being compiled and collated in a 3D model showing the geologic controls and assay results. This compilation will be used to design the next drill phase, which is expected to be announced in the near future.

To view full results of the sampling and drill program on the La Negra property, visit: www.kootenaysilver.com

The foregoing geological disclosure has been reviewed and verified by Kootenay’s CEO, James McDonald, P.Geo (a qualified person for the purpose of National Instrument 43-101, Standards of Disclosure for Mineral Projects). Mr. McDonald is a director of Kootenay.

About Kootenay Silver

Kootenay Silver Inc. is actively developing mineral projects in the Sierra Madre Region of Mexico and in British Columbia, Canada. Its flagship property is the former producing Promontorio Silver mine in Sonora State, Mexico. Kootenay’s objective is to develop near term discoveries and long-term sustainable growth. Its management and technical team are proven professionals with extensive international experience in all aspects of mineral exploration, operations and venture capital markets. Multiple, ongoing J/V partnerships in Mexico and Canada maximize potential for additional, new discoveries while maintaining minimal share dilution.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: The information in this news release has been prepared as at August 10, 2015.  Certain statements in this news release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” under the provisions of Canadian provincial securities laws.  These statements can be identified by the use of words such as “expected”, “may”, “will” or similar terms.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by Kootenay as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies.  Many factors, known and unknown, could cause actual results to be materially different from those expressed or implied by such forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.  Except as otherwise required by law, Kootenay expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Kootenay’s expectations or any change in events, conditions or circumstances on which any such statement is based. More particularly, this release contains statements concerning the closing of the balance of the Private Placement and the commencement of the next phase of a drilling program on the La Negra property. Accordingly, there is a risk that the Private Placement will not be completely sold, completed within the anticipated time or at all, and that the drilling program will not be commenced or completed as currently contemplated.. 

Cautionary Note to US Investors: This news release may contain information about adjacent properties on which we have no right to explore or mine. We advise U.S. investors that the SEC’s mining guidelines strictly prohibit information of this type in documents filed with the SEC. U.S. investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, the completion of the Private Placement, the proposed use of the proceeds of the Private Placement, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

This press release uses the terms “Measured”, “Indicated”, and “Inferred” resources. United States investors are advised that while such terms are recognized and required by Canadian regulations, the United States Securities and Exchange Commission does not recognize them. “Inferred Mineral Resources” have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. Under Canadian rules, estimates of Inferred Mineral Resources may not form the basis of feasibility or other economic studies. United States investors are cautioned not to assume that all or any part of Measured or Indicated Mineral Resources will ever be converted into Mineral Reserves. United States investors are also cautioned not to assume that all or any part of a Mineral Resource is economically or legally mineable.

SOURCE Kootenay Silver Inc.

Cartier Resources {TSX.V: ECR} have confirmed they have closed a flow through private placement  to accredited investors of $143,000.

This figure included insider participation to the tune of $15,600.

CARTIER CLOSES A PRIVATE PLACEMENT FOR A TOTAL OF $143,000

Cartier Resources Inc.{TSX.V: ECR} has closed a flow through private placement for $143,000, issuing units at 13c.

The private placement is a flow-through private placement with accredited investors and consists of 110 units for an amount of $143,000.

For the flow-through private placement, each unit, at a price of $1,300 per unit, is composed of 10,000 flow-through common shares at a price of 13 cents per share. Thus, the following securities were issued by Cartier — 1.1 million flow-through shares at a price of 13 cents per share for an amount of $143,000. Two insiders participated in this financing for a total of 120,000 shares ($15,600).

The securities issued under the private placement are subject to a four-month-and-one-day statutory hold period.

The proceeds of the placement will be used by Cartier to conduct exploration on the Benoist, Cadillac Extension and MacCormack projects.

Inovio Pharmaceuticals Inc. {NASDAQ: INO} and Medimmune have today conformed that they have entered into a strategic collaboration and licence agreement for strategic cancer vaccine.

Medimmune is the biologics division of Astra Zenica

INOVIO PHARMACEUTICALS ENTERS INTO STRATEGIC CANCER VACCINE COLLABORATION AND LICENSE AGREEMENT WITH MEDIMMUNE

Agreement includes clinical-stage INO-3112 HPV cancer vaccine and pre-clinical collaboration to develop additional cancer vaccine candidates.
PLYMOUTH MEETING, Pa. – August 10, 2015 – Inovio Pharmaceuticals {NASDAQ: INO} today announced that it has entered into a license agreement and collaboration with Medimmune, the global biologics research and development arm of AstraZeneca.

Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers.

MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune’s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells.

Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to Inovio as well as potential future payments upon reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales.

Within the broader collaboration, MedImmune and Inovio will develop up to two additional DNA-based cancer vaccine products not included in Inovio’s current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products.

Dr. David Berman, Senior Vice President and Head of the Oncology Innovative Medicines unit, MedImmune, said: “Today’s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific T-cell responses. The unique combination of our broad immuno-oncology portfolio with Inovio’s T-cell-activating INO-3112, which enhances cancer specific killer T-cells, has the potential to deliver real clinical benefits for patients.”

Dr. J. Joseph Kim, President and CEO, Inovio, said: “Our licensing partnership with MedImmune represents an important step in executing our immuno-oncology combination strategy and advancing Inovio’s cancer vaccine R&D pipeline with a leading cancer immunotherapy company. INO-3112 is progressing, with positive interim data generated in an Inovio-initiated phase I study. We appreciate MedImmune’s recognition of our ability to activate best-in-class killer T-cells in vivo and look forward to working with them on this collaboration.”

Today’s agreement builds on the existing partnership between Inovio and MedImmune on two research and development collaborations in the infectious disease area. Both efforts are funded by the Defense Advanced Research Projects Agency (DARPA) and support R&D focused on Ebola, influenza, and bacterial infections. MedImmune has a strong heritage in infectious disease and vaccine innovation, having developed the first monoclonal antibody approved by the US Food & Drug Administration for the prevention of an infectious disease and the technology that led to the creation of an HPV vaccine.

 
About INO-3112
Inovio’s SynCon® DNA-based immunotherapies help the immune system activate disease-specific killer T cells to fight a targeted disease. HPV, the most pervasive sexually transmitted virus, causes numerous pre-cancers and cancers. Inovio’s HPV immunotherapy called INO-3112 targets disease associated with the high-risk HPV types 16 and 18, which are responsible for over 70% of cervical pre-cancers and cancers. INO-3112 combines Inovio’s VGX-3100, its immunotherapy targeting HPV-caused diseases, with its DNA-based immune activator encoded for IL-12. INO-3112 is in three clinical studies for cervical and head and neck cancers.

Earlier this year, Inovio reported preliminary data showing that INO-3112 generated significant antigen-specific CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. These positive results represent the first study and first report of antigen-specific T cell immune responses generated in cancer patients after treatment with a DNA immunotherapy.

Previously in a phase II efficacy trial, treatment with VGX-3100 resulted in histopathological regression of late-stage cervical dysplasia to early stage or no disease, meeting the study’s primary endpoint. In addition, the trial demonstrated clearance of the HPV virus in conjunction with regression of cervical lesions, meeting the secondary endpoint. Robust T-cell activity was observed in subjects who received VGX-3100 compared to those who received placebo.

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers.

For more information, please visit www.medimmune.com

About AstraZeneca in Oncology
Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. It will be potentially transformational for the company’s future, becoming the sixth growth platform. Their vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.

Their broad pipeline of next-generation medicines is focused on four main disease areas – ovarian, lung, breast and hematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information please visit: www.astrazeneca.com

About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. Their immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline.

Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com
CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals

+1 858-410-3101

bhertel@inovio.com

# # # #

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended June 30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Barkerville Gold Mines. {TSXV: BGM} have announced a strategic agreement with Osisko Gold Royalties.

This agreement grants Osisko first offer and first right of refusal on future royalties on BGM’s Cow Mountain Project.

TORONTO, ON – July 29, 2015 – Barkerville Gold Mines. {TSXV: BGM} is pleased to announce it has entered into an agreement with Osisko Gold Royalties Ltd. granting Osisko the Right of First Offer and the Right of First Refusal on future royalties on the Company’s Cow Mountain Project on the Caribou Gold Trend, British Columbia.

In return for this consideration, Osisko has recently invested a total of $5,000,000 in flow through funds to advance the Company’s gold project and has extended the Company access to use their exploration and mining services team to complement their newly recruited exploration staff.

The Company also wishes to announce the appointments of Mr. Chris Lodder and Mr. Allan J. Folk to the board of directors.

Mr. Lodder has 25 years’ experience working on and managing Greenfields and Brownfields exploration with major and junior mining companies worldwide with the majority of his career focused in the Americas. Mr. Lodder is the President of Talisker Exploration Services Inc., an Ontario based Mining and exploration services company founded by Mr. Lodder in 2010, whose principal clients are Osisko Gold Royalties and their associated companies. From 1999 to 2010 he was South American Exploration Manager and later the Americas Exploration Manager for AngloGold Ashanti. He is widely recognized as the person responsible for the proposal, execution and management of AngloGold Ashanti’s successful Greenfields exploration program in Colombia, with the discoveries of the La Colosa and Gramalote deposits. Mr. Lodder’s team also discovered the La Rescatada Project now known as the Andres Mine in Peru.

Mr. Folk brings to the board over 35 years’ experience in the investment industry with a bias toward the resource sector. He is currently the Vice President of Brant Securities and serves as Vice President of Institutional Equity Sales at Forte House Inc. Mr. Folk also serves as Vice Chairman of Atlanta Gold Inc. and serves as a director of Oremex Silver Inc.

President and CEO of BGM Tom Obradovich stated: “The transition of BGM has been rapid and focussed. The Company is now well funded and debt free, with Osisko as a strategic partner and the valuable additions of Mr. Lodder and Mr. Folk to the board, we are on a clear path to developing one of North America’s premier gold camps.”

For further information on Barkerville Gold Mines Ltd., please contact:

Tom Obradovich
President & Chief Executive Officer
+1 416 361-2511
tobradovich@sympatico.ca

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange (“TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

The S&P/TSX Venture Composite Index – {TSX: VIJX}, commonly known as the Toronto Venture Exchange has lost 45% in value in the last year.

This is quite an incredible and alarming drop for a single year, and only highlights the issues the Venture is facing. What are the causes for this fall?

It is very sobering to realise that the Toronto Venture Exchange,  {TSX: VIJX}, has lost 45% in value in the last 12 months!

Only one year ago the index stood at the heady heights of 1050, having fallen from the recent high of 2450 in January 2011, and the all time high of 3350, reached in 2007.

Clearly with around 70% of the index consisting of junior resource companies, and with the “commodities supercycle” now seriously off the rails, with falling prices of gold, copper, oil, etc.etc.a fall is to be expected, of course.  What is not to be expected is the severity of the fall, which is becoming precipitous, and  begs the obvious question, why has the index fallen so far,and continues to fall?

Currently, 66% of mining companies listed on the TSX. Venture Exchange have a market cap of CAD $1 million or under!   That is an incredible fact, and as stock values continue to fall, along with commodity prices, it is also a number that is increasing!

These vast majority,if not all these companies have no real future as investments, in the current low and falling commodity price environment, they are simply hanging on doing smaller and smaller “keep the lights on and pay the salaries” type financings amongst friends and insiders, and this surely cannot continue for much longer?

Their continued presence on the Exchange is almost embarrassing, but their listing fees of around CAD $35,000 per company per year are readily accepted by the exchange of course!

I think the answer is fairly obvious, and  simply that far too many of the companies listed on the Venture Exchange are clearly lifestyle vehicles for the management, and not looking after shareholder interests.

It’s about time that people started to look at the accounts of companies they are invested in, or are contemplating investing in!

In particular, they should refer to the the Related Party section of the accounts, which is conveniently located at the very end (for obvious reasons!), of 20 or 30 mind numbingly boring pages of property descriptions and endless tables of figure.

They can be very illuminating!  In addition to showing the the CEO’s salary, and remunerations of other directors, this is where you can often find management rewarding themselves in other, obscure ways.

The favourites are;

• A director is being paid for legal services provided to the company.
• A director is being paid for geological services tot he company.
• A company owned by a director is being paid for the office rental.
• A company owned by a director is being paid to provide secretarial services.
• A director is being paid for ‘consultancy services’ to the company.
• A director vending in a property he already owns for a large price than he paid for it.
• A director owning the drilling company that performs the work for the company.

The amounts involves can sometimes be eye watering, and the name of the recipient director, nor a description of the ‘consultancy services’ provided will ever be given.

When a CEO or director is asked his remuneration, he will only quote his standard salary figure, not the figure actually earned inclusive of his additional earnings.

I have learned to always check the Related Party section of the accounts before I make an investment decision in any company,as they tell the real story!  Many companies have an empty section here because they are running in a transparent and honest way, and these are the companies I will consider investing in.

Incredibly

Carlisle Goldfields Ltd. {TSX.V: CGJ} announced the results of their quarterly infill drilling update from their JV partner at Lynn lake, Alamos Gold.

Of particular note was drill hole FL15-38 which intersected 16.4 gpt over 9.3metres.

CARLISLE GOLDFIELDS ANNOUNCES INFILL DRILL RESULTS ON THE FARLEY LAKE MINE PROJECT, INCLUDING 16.4 G/T GOLD OVER 9.3M

Carlisle Goldfields Ltd. }TSX.V: CGJ} has released the results of a quarterly feasibility update from joint venture partner Alamos Gold Inc. These include interim results from an initial 4,841.2 metres of drilling in 38 holes on the 2015 feasibility-level infill drill program at the Farley Lake mine project. While several holes were also dedicated to condemnation testing of the modelled deposit margins, drill hole FL15-38 also intersected 16.4 grams per tonne gold over 9.3 metres between 212 metres to 221.8 metres downhole.

Carlisle’s President and chief executive officer, Abraham Drost, commented: “Assays from the initial 38 holes from the feasibility infill drill program continue to showcase the Farley Lake mine project’s considerable gold grade potential. Meanwhile, infill drilling with three rigs has also commenced at the MacLellan deposit. The forthcoming mineral resource update for both Farley Lake and MacLellan will support commencement of the formal feasibility study referenced in the April 28, 2015, feasibility study update.”

Carlisle’s partner, Alamos Gold, {TSX: AGI}, as operator, has a 25-per-cent interest in the Lynn Lake joint venture and has the right to increase its interest to 51 per cent by spending $20-million on the advancement of a feasibility study by Nov. 10, 2017. Alamos may increase its interest in the Lynn Lake joint venture to a maximum of 60 per cent by delivering a compliant feasibility study within the same period.

The partners are also jointly financing a $4-million special exploration program outside the feasibility study area in calendar 2015. Carlisle is the operator of special exploration on the balance of the approximately 38,000-hectare Lynn Lake joint venture land position.

 
                     2015 SECOND QUARTER ASSAY HOLE LOCATIONS 
                FARLEY LAKE PROJECT, 2015 FEASIBILITY INFILL DRILLING
  
Hole ID       From      To     Length      Au        Sample    Weighted average     Interval
                (m)     (m)        (m)   (g/t)                          Au (g/t)          (m)

FL15-01      40.37   40.90       0.53     0.41       775022
FL15-01      89.00   90.50       1.50    11.50       775072
FL15-02      No data
FL15-03      No significant results
FL15-04      28.26   29.00       0.74    16.05       777517
FL15-04      79.80   80.30       0.50     1.78       777561
FL15-05     117.50  118.50       1.00     2.39       775338
FL15-05     186.00  187.00       1.00     1.97       775414
FL15-05     207.60  208.20       0.60     3.43       775437                1.07         2.40
            208.20  209.00       0.80     0.04       775438
            209.00  210.00       1.00     0.48       775439
FL15-06      30.50   31.50       1.00     0.49       777617
FL15-07     No significant results
FL15-08      44.65   45.65       1.00     3.00       777687                2.17         1.55
             45.65   46.20       0.55     0.66       777688
FL15-08     116.10  117.10       1.00     0.88       777764
FL15-09      19.95   20.85       0.90     0.84       775522
FL15-09      26.85   27.85       1.00     0.49       775530                0.48         2.95
             27.90   28.85       0.95     0.47       775531
             28.85   29.85       1.00     0.48       775532
FL15-09      44.20   45.20       1.00     1.09       775546
FL15-09      71.00   72.24       1.24     0.83       775574
FL15-09     103.96  104.96       1.00    22.60       775609                8.18         2.82
            104.96  106.00       1.04     0.16       775610
            106.00  106.78       0.78     0.39       775611
FL15-09     137.74  138.74       1.00     1.47       775646                1.97         5.26
            138.74  139.74       1.00     2.46       775647
            139.74  140.74       1.00     4.94       775648
            140.74  141.74       1.00     0.37       775649
            141.74  143.00       1.26     0.91       775650
FL15-10      30.50   31.40       0.90     1.26       777826                2.44         2.90
             31.40   32.40       1.00     5.55       777827
             32.40   33.40       1.00     0.40       777828
FL15-11      25.00   26.00       1.00     2.97       777868
FL15-11      30.00   31.00       1.00     4.50       777873
FL15-12      34.20   35.00       0.80     0.46       775676
FL15-13      54.40   54.90       0.50     3.77       777961
FL15-13      91.30   92.00       0.70     2.06       778001
FL15-14     100.00  101.00       1.00    15.20       775814
FL15-14     109.00  110.00       1.00     0.79       775827
FL15-14     118.00  119.00       1.00     3.52       775837
FL15-14     130.00  131.00       1.00     0.42       775850
FL15-14     150.00  151.00       1.00     1.85       775871
FL15-14     177.00  178.00       1.00     0.41       775902
FL15-14     184.50  185.00       0.50     4.99       775910                4.90         5.50
            185.00  186.10       1.10     1.19       775911
            186.10  187.00       0.90     0.32       775912
            187.00  187.50       0.50     3.78       775913
            187.50  188.00       0.50     3.73       775914
            188.00  189.00       1.00     0.21       775915
            189.00  189.50       0.50    35.40       775916
            189.50  190.00       0.50     2.36       775918
FL15-15      19.00   20.00       1.00     0.42       775930
             42.50   43.00       0.50     3.17       775955
            156.00  156.50       0.50     0.48       776083
            156.50  157.00       0.50     0.51       776084
FL15-16      72.70   73.50       0.80     2.84       778068
FL15-16     132.50  133.00       0.50     0.88       778135
FL15-16     134.50  135.45       0.95     0.41       778138
FL15-16     137.40  138.40       1.00     0.68       778142
FL15-16     158.00  158.50       0.50     0.44       778166
FL15-17      70.00   71.00       1.00     8.66       778705
FL15-17      74.00   75.00       1.00     3.32       778709
FL15-17      81.00   82.00       1.00     0.91       778716
FL15-17      88.00   89.00       1.00     2.34       778724
FL15-17      91.00   92.00       1.00     0.84       778728
FL15-17     139.00  140.00       1.00     0.52       778780
FL15-18      39.45   40.10       0.65     0.50       776135
FL15-18      44.35   45.40       1.05     2.38       776142
FL15-18      49.40   50.20       0.80     0.86       776147
FL15-18      90.00   91.00       1.00    26.80       776191
FL15-19      36.00   37.00       1.00     4.42       778810               11.70        10.60
             37.00   38.00       1.00    19.15       778811
             38.00   39.00       1.00    10.85       778812
             39.00   39.80       0.80    10.20       778813
             39.80   40.40       0.60    12.60       778814
             40.40   41.00       0.60     9.13       778815
             41.00   41.50       0.50    17.50       778816
             41.50   42.00       0.50     7.71       778817
             42.00   43.00       1.00    10.35       778818
             43.00   43.50       0.50     8.29       778819
             43.50   44.00       0.50    13.70       778821
             44.00   44.50       0.50    18.70       778822
             44.50   45.30       0.80    13.65       778823
             45.30   46.00       0.70    17.55       778824
             46.00   46.60       0.60     3.09       778826
FL15-19      97.00   98.00       1.00     0.90       778882                0.69         3.00
             98.00   99.00       1.00     0.40       778883
             99.00  100.00       1.00     0.77       778884
FL15-20A     49.00   50.00       1.00     0.61       776264
FL15-20A     88.00   89.00       1.00     1.21       776306                2.56         3.00
             89.00   90.00       1.00     5.23       776307
             90.00   91.00       1.00     1.24       776309
FL15-20A    101.05  101.55       0.50     6.72       776321
FL15-21       8.10    9.00       0.90     0.41       778233                3.87         4.00
              9.00    9.60       0.60     1.32       778234
              9.60   10.20       0.60     3.47       778235
             10.20   10.80       0.60    11.80       778236
             10.80   11.60       0.80     0.21       778237
             11.60   12.10       0.50     9.94       778238
FL15-21      42.00   43.00       1.00     0.91       778274
FL15-21      50.50   51.08       0.58     0.47       778285
FL15-21      59.80   60.30       0.50     5.45       778295                4.85         4.20
             60.30   60.80       0.50     2.89       778296
             60.80   61.40       0.60     9.43       778297
             61.40   62.00       0.60     7.40       778298
             62.00   63.00       1.00     2.25       778299
             63.00   64.00       1.00     3.85       778301
             65.75   66.75       1.00     4.80       778304
FL15-21      69.75   70.75       1.00     0.44       778308                3.22        9.355
             70.75   71.75       1.00     3.50       778309
             71.75   72.75       1.00     0.09       778310
             72.75   73.75       1.00     0.84       778311
             73.75   74.30       0.55     0.03       778312
             74.30   75.30       1.00     1.45       778313
             75.30   76.30       1.00     2.48       778314
             76.30   77.10       0.80     0.07       778315
             77.10   78.10       1.00     2.48       778316
             78.10   79.10       1.00    18.75       778317
FL15-21     104.00  105.00       1.00     3.81       778346                1.55         4.00
            105.00  106.00       1.00     1.63       778347
            106.00  107.00       1.00     0.24       778348
            107.00  108.00       1.00     0.50       778349
FL15-21     116.00  117.00       1.00     0.55       778358
FL15-21     121.50  122.50       1.00     0.81       778364
FL15-21     131.00  132.00       1.00     0.40       778373
FL15-21     166.30  167.30       1.00     3.16       778411
FL15-21     173.00  174.00       1.00     0.44       778418                1.06         2.00
            174.00  175.00       1.00     1.68       778419
FL15-21     182.00  183.00       1.00     0.51       778429                5.54         4.60
            183.00  183.70       0.70     0.01       778430
            183.70  184.40       0.70     0.01       778431
            184.40  184.90       0.50    15.15       778432
            184.90  185.40       0.50     0.10       778433
            185.40  186.10       0.70     7.38       778434
            186.10  186.60       0.50    24.30       778435
FL15-21     194.00  195.00       1.00     0.63       778445
FL15-22      35.00   36.00       1.00     0.59       778909
FL15-22      41.00   42.00       1.00     2.06       778915                3.40         2.08
             42.00   43.08       1.08     4.64       778916
FL15-22      54.00   54.60       0.60     3.29       778931
FL15-23      44.30   45.00       0.70     2.53       779022                4.61         6.10
             45.00   46.10       1.10     1.00       779023
             46.10   47.10       1.00     9.98       779024
             47.60   48.00       0.40     5.35       779026
             48.00   48.90       0.90     5.25       779027
             48.90   49.80       0.90     6.71       779028
             49.80   50.90       1.10     2.16       779029
FL15-23      72.20   73.40       1.20     0.83       779048
FL15-24      No significant results
FL15-25      30.00   31.00       1.00     9.51       778461                5.30         3.30
             31.00   32.00       1.00     3.42       778462
             32.00   32.60       0.60     3.91       778463
             32.60   33.30       0.70     3.17       778464
FL15-25      49.00   50.00       1.00     1.31       778483
FL15-25      86.00   87.10       1.10     0.89       778518
FL15-25     114.90  115.90       1.00     3.27       778546
FL15-26      31.50   32.30       0.80     0.71       776338                0.55         1.80
             32.30   33.30       1.00     0.42       776339
FL15-26      73.00   74.00       1.00     1.03       776783                6.34         2.00
             74.00   75.00       1.00    11.80       776784
             75.00   76.00       1.00     0.87       776785
FL15-26      79.00   80.00       1.00     0.47       776789                3.43         2.00
             80.00   81.00       1.00     1.59       776790
             81.00   82.00       1.00     5.26       776791
FL15-27      87.00   87.95       0.95     1.83       779268                9.36         2.75
             87.95   88.75       0.80    29.40       779269
             88.75   89.75       1.00     0.49       779270
FL15-28      No significant results
FL15-29      14.00   15.25       1.25     1.04       776354
FL15-29      17.50   18.20       0.70     2.75       776357
FL15-29      21.20   22.20       1.00     0.85       776362                0.94         8.00
             22.20   23.20       1.00     0.65       776363
             23.20   24.20       1.00     0.80       776364
             24.20   25.20       1.00     0.16       776365
             25.20   26.20       1.00     1.19       776366
             26.20   27.20       1.00     1.62       776367
             27.20   28.20       1.00     1.73       776368
             28.20   29.20       1.00     0.48       776369
FL15-30     106.20  107.20       1.00     0.74       778639
FL15-30     141.80  142.40       0.60     0.56       778674                8.71         1.70
            149.00  149.90       0.90     3.88       778685
            149.90  150.70       0.80    14.15       778686
FL15-31      No significant results
FL15-32      No significant results
FL15-33      47.00   47.80       0.80     0.96       714293                2.06         2.00
             47.80   48.30       0.50     5.93       714294
             48.30   49.00       0.70     0.55       714295
FL15-33      52.20   52.70       0.50     5.81       714299
FL15-33      64.00   65.00       1.00     0.47       714312
FL15-33      70.00   71.00       1.00     3.33       714318
FL15-33      73.20   74.00       0.80     0.62       714322
FL15-33      75.00   75.50       0.50     0.86       714324
FL15-33      89.00   90.00       1.00     0.61       714341
             90.00   91.00       1.00     2.35       714342
             94.00   94.50       0.50     4.34       714346
FL15-33     100.50  101.50       1.00     0.40       714353                4.26        12.00
            101.50  102.50       1.00     0.82       714354
            102.50  103.50       1.00     0.32       714355
            103.50  104.50       1.00     0.52       714356
            104.50  105.50       1.00     1.14       714357
            105.50  106.20       0.70     3.48       714358
            106.20  106.80       0.60    11.70       714359
            106.80  107.60       0.80     4.85       714361
            107.60  108.30       0.70     2.58       714362
            108.30  109.00       0.70    35.10       714363
            109.00  109.90       0.90     2.22       714364
            109.90  110.40       0.50     0.33       714365
            110.40  111.00       0.60     2.65       714366
            111.00  111.80       0.80     0.49       714367
            111.80  112.50       0.70     5.84       714368
FL15-33     116.50  117.50       1.00     1.07       714373                2.95         8.20
            117.50  118.50       1.00     0.18       714374
            118.50  119.20       0.70     4.36       714376
            119.20  119.80       0.60     4.06       714377
            119.80  120.80       1.00     0.88       714378
            120.80  121.60       0.80     0.60       714379
            121.60  122.50       0.90     0.54       714381
            122.50  123.10       0.60     4.01       714382
            123.10  123.70       0.60    18.80       714383
            123.70  124.70       1.00     1.92       714384
FL15-33     128.40  129.40       1.00     5.51       714389                3.34         2.00
            129.40  130.40       1.00     1.16       714390
FL15-33     134.00  134.50       0.50     8.59       714395
FL15-33     146.50  147.60       1.10     2.06       714409                3.34         2.00
            147.60  148.50       0.90     0.92       714410
FL15-34       9.00   10.00       1.00     2.32       714001                7.09         2.00
             10.00   11.00       1.00    11.85       714002
FL15-34      26.30   26.90       0.60    83.30       714018               21.90         2.40
             26.90   27.90       1.00     0.30       714020
             27.90   28.70       0.80     2.86       714021
FL15-34      66.20   66.70       0.50     1.89       714063                2.59         1.00
             66.70   67.20       0.50     3.28       714064
FL15-34     103.70  104.70       1.00     0.75       714105                1.36         4.00
            104.70  105.70       1.00     1.96       714106
            105.70  106.70       1.00     1.62       714107
            106.70  107.70       1.00     1.11       714108
FL15-34     119.00  120.00       1.00     5.45       714120
FL15-34     165.00  166.00       1.00     0.86       714172                1.95        17.00
            166.00  167.00       1.00     0.47       714173
            167.00  167.90       0.90     0.88       714174
            167.90  168.50       0.60     4.29       714176
            168.50  169.50       1.00     2.18       714177
            169.50  170.40       0.90     2.38       714178
            170.40  171.10       0.70     2.32       714179
            171.10  172.00       0.90     4.97       714181
            172.00  173.00       1.00     2.53       714182
            173.00  174.00       1.00     1.05       714183
            174.00  175.00       1.00     2.61       714184
            175.00  176.00       1.00     0.89       714185
            176.00  177.00       1.00     0.45       714186
            177.00  178.00       1.00     0.97       714187
            178.00  179.00       1.00     0.91       714188
            179.00  180.00       1.00     3.59       714189
            180.00  181.00       1.00     4.39       714190
            181.00  182.00       1.00     0.58       714191
FL15-34     202.00  203.00       1.00     3.88       714213
FL15-34     227.00  228.00       1.00     0.51       714241
FL15-35     No significant results
FL15-36     50.00   51.00        1.00     3.46       776551                1.99         2.00
            51.00   52.00        1.00     0.51       776552
FL15-36     61.80   62.50        0.70     0.91       776564                4.82         1.50
            62.50   63.30        0.80     8.24       776565
FL15-36     66.70   67.20        0.50     1.18       776570
FL15-36     79.00   80.00        1.00     1.38       776585
FL15-36     90.50   91.00        0.50     1.52       776596
FL15-36    102.00  102.70        0.70     0.76       776609                8.84         2.00
           102.70  103.40        0.70     5.21       776610
           103.40  104.00        0.60    22.50       776611
FL15-36    106.00  107.00        1.00     0.75       776615                2.62        19.50
           117.90  118.20        0.30     5.82       776629
           122.00  122.80        0.80     4.70       776634
           128.00  128.80        0.80     1.34       776641
           128.80  129.50        0.70     2.22       776642
           129.50  130.10        0.60     6.75       776643
           130.10  130.70        0.60     1.65       776644
           130.70  132.00        1.30     0.38       776645
           132.00  133.00        1.00     0.35       776646
           133.00  133.80        0.80     0.84       776647
           133.80  134.70        0.90    10.50       776648
           134.70  136.00        1.30     1.06       776649
           136.00  136.60        0.60     0.09       776650
           136.60  137.20        0.60     5.11       776651
           137.20  137.80        0.60    16.35       776652
           137.80  138.70        0.90     3.82       776653
           138.70  139.40        0.70     0.50       776654
           139.40  140.40        1.00     7.09       776655
           140.40  140.90        0.50     0.09       776656
           140.90  142.00        1.10     1.04       776657
           142.00  143.00        1.00     1.12       776658
           143.00  144.00        1.00     0.73       776659
           144.00  144.80        0.80     0.86       776661
           144.80  146.00        1.20     0.71       776662
           146.00  147.00        1.00     0.30       776663
           147.00  147.50        0.50     4.87       776664
FL15-36    163.00  164.00        1.00     2.73       776679
FL15-37     No significant results
FL15-38     95.00   95.50        0.50     0.55       714497
FL15-38    205.22  206.00        0.78     0.46       714612
FL15-38    212.00  213.00        1.00     0.92       714619               16.47         9.38
           213.00  214.00        1.00     0.54       714621
           214.00  214.75        0.75     0.78       714622
           214.75  215.50        0.75     1.50       714623
           215.50  216.13        0.63     7.26       714624
           216.13  216.80        0.67   171.00       714626
           216.80  218.00        1.20     1.07       714628
           218.00  219.13        1.13     0.99       714629
           219.13  219.80        0.67    23.10       714630
           219.80  220.67        0.87    11.60       714631
           220.67  221.38        0.71     5.90       714632
FL15-38    237.00  237.57        0.57     1.40       714650

True-width calculations indicate that core length 
is in excess of 90 per cent of core length.

Quality assurance/quality control

The Alamos drill program is carried out under the supervision of Mark Rein, PGeo, senior project geologist and a qualified person as defined by National Instrument 43-101.

Samples were transported directly in secure containers from the Alamos core handling facility in Lynn Lake, Man., to the ALS Chemex Laboratories in Thunder Bay, Ont. ALS Chemex, which is an accredited ISO/IEC 17025 lab, assayed the samples using standard fire assay methods with a gravimetric finish. Certified standards are placed in the sample stream at a rate of one standard per 20 samples. Certified blanks are placed in the sample stream at a rate of one blank every 40 samples. One lab reject duplicate per 30 samples is submitted to an umpire lab for assay verification. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used.

Peter Karelse, PGeo, vice-president, exploration, for Carlisle Goldfields and a qualified person (as defined by NI 43-101), has reviewed and approved the technical content of this press release.

We seek Safe Harbor.

Avalon Rare Metals {TSX:AVL} has recieved a letter of non compliance form the NYSE.

As a result, in order to comply with the NYSE’ listing requirements, either AVL will have to trade at a higher share price within the time frame stipulated, or action a share consolidation, which will need shareholder approval.

Comment

This is a bit ridiculous, as the regulation referred to here stipulates;

“(b) Stock Price/Market Value of Shares Publicly Held—The Exchange requires a minimum market price of $3 per share for applicants seeking to qualify for listing pursuant to Section 101 (a), (b) or (d), a minimum market price of $2 per share for applicants seeking to qualify for listing pursuant to Section 101(c), and $3,000,000 aggregate market value of publicly held shares for applicants seeking to qualify for listing pursuant to Section 101(a).”

So, in order to regain compliance, Avalon will have to action a share consolidation to increase the share price to the required minimum!

The market cap remains the same, so what’s the point? What is the advantage to the shareholder?  And what will it cost to action this?

I guess Avalon will do as requested as they have US based investors and won’t want to de-list in this market.

News release

TORONTO, Aug. 5, 2015 – Avalon Rare Metals {TSX: AVL} has received a letter from NYSE MKT LLC dated July 30, 2015 which states that due to the Company’s recent low selling share price, it has been deemed to be not in compliance with the continued listing standards of the Exchange.

Pursuant to Section 1003(f)(v) of the Exchange’s Company Guide, the Company’s continued listing is contingent upon the Company effecting a share consolidation within a reasonable period of time or upon a sustained increase in its share price.

A potential share consolidation, if required, will need to be approved by the Company’s shareholders at the Company’s next annual general meeting currently planned for February, 2016.

About Avalon Rare Metals Inc.

Avalon Rare Metals Inc. is a mineral development company focused on rare metal deposits in Canada, with three advanced stage projects. Its 100%-owned Nechalacho Deposit, Thor Lake, NWT is exceptional in its large size and enrichment in the scarce “heavy” rare earth elements, key to enabling advances in clean technology and other growing high-tech applications. Avalon is also advancing its Separation Rapids Lithium Minerals Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback;

e-mail the Company at ir@avalonraremetals.com

Or phone Don Bubar, President & CEO at +1 416 364 4938.

Cautionary Statement

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements regarding the continued listing of the Company’s securities. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “potential”, “scheduled”, “anticipates”, “continues”, “expects” or “does not expect”, “is expected”, “scheduled”, “targeted”, “planned”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be” or “will not be” taken, reached or result, “will occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avalon to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. Although Avalon has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to market conditions, as well as those risk factors set out in the Company’s current Annual Information Form, Management’s Discussion and Analysis and other disclosure documents available under the Company’s profile at www.SEDAR.com.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements have been provided for the purpose of assisting investors in understanding the Company’s plans and objectives and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements. Avalon does not undertake to update any forward-looking statements that are contained herein, except in accordance with applicable securities laws.

Nymox Pharmaceutical Corp. (NASDAQ: NYMX} has confirmed they are re-domiciling in the Bahamas.

This follows shareholder approval and Corporations Canada agreeing to the change.

HASBROUCK HEIGHTS, N.J. — Nymox Pharmaceutical Corp. (NASDAQ: NYMX} is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas, effective July 31, 2015.

At the Special Shareholders Meeting of Nymox on April 23, 2015 there was a 94% majority shareholder vote in favor of the Company’s change of domicile to the Bahamas.

Subsequent to the majority vote in favor, on July 31, 2015 the Company was informed that it has received formal approval from Corporations Canada. The Company’s Management are located in Bahamas, the U.S. and Europe. The Company currently maintains offices in the Bahamas, the U.S. and Canada.

The Company recently announced that it’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies.

The Company now intends to meet with authorities and to proceed to file where possible, in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories.

Nymox has also recently reported a successful Phase 2 long-term outcome study in 147 men of NX-1207 at higher dosage for low grade localized prostate cancer.

The July 27^th webcast of news and discussion by experts of the Company’s new clinical trial results can be viewed at

http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html.

The link is also available at the Company’s website.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH, the potential of NX-1207 to treat BPH and the estimated timing of further developments for NX-1207. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on NX-1207, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of NX-1207. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.

Contact:

Paul Averback Nymox Pharmaceutical Corporation

www.nymox.com

WesternZagros Resources  {TSX.V: WZR}  has released a market update in advance of their Q2 results due on 13th August.

The focus is on the news that the Sarqala 1 well in their Garmian block has averaged 5,427 BOPD in Q2 2015.

Aug 4, 2015 – 07:30 AM ET

WesternZagros Resources Ltd.: Update From CEO

CALGARY, ALBERT– Aug. 4, 2015) – WesternZagros Resources  {TSX.V: WZR}  is committed to providing timely and accurate information about its business strategy and objectives, financial and operating results, and development plan advancements. In addition to regulatory and materially-driven news releases, the Company invites investors and stakeholders to stay informed of its activity in the Kurdistan Region of Iraq through this newly-initiated status update.

This periodic update comes in advance of the Company’s standard second quarter results which are scheduled for release on August 13, 2015.

Garmian Block

Second quarter production from the Sarqala-1 well averaged 5,427 barrels of oil per day (“bbl/d). WesternZagros continues, in accordance with the KRG, to supply this production to the domestic market under pre-paid contracts. The Company currently has two domestic customers for its oil production.

The Company is incorporating final comments from the Kurdistan Regional Government (“KRG”) into its Sarqala Field Development Plan (“FDP”). Approval of the FDP is expected once the KRG has completed its contractual negotiations to build a natural gas plant to utilize the associated natural gas from the Sarqala field.

Operations to suspend the Hasira-1 well are proceeding according to plan and are anticipated to be completed in the third quarter. Although the FDP will delineate and develop the resources within the Jeribe reservoir, the Company and its partner, Gazprom Neft, are actively discussing the most effective next steps and the timing to assess the potential of Hasira-1’s Mio-Oligocene oil discovery.

The Company has prepared the Sarqala-2 well site and is ready to spud the well, which is expected to occur in the fourth quarter, once the Hasira-1 suspension operations are completed and the Sarqala FDP is approved by the KRG.

Kurdamir Block

Following the Repsol S.A. (“Repsol”) acquisition of Talisman Energy Inc. in early May 2015, the Company is now actively engaged with Repsol on advancing the Kurdamir Development Plan. The KRG is keen to progress this oil and gas project although it is anticipated to take until the first quarter of 2016 for the co-venturers to finalize the development plan.

Corporate & Financial

Pursuant to the terms of the Investment Agreement between the Company and Crest dated March 10, 2013 as amended, Crest is in active discussions with the Company to appoint two directors to the WesternZagros Board. The Company welcomes these future appointments as the Company executes on its strategic and financial priorities.

In light of the ongoing oil price environment, the Company continues to implement strict cost reduction efforts that have meaningful impact to the bottom line, including optimizing capital investment, renegotiating contracts with service companies and cutting discretionary expenditures. The Company’s priorities are to manage capital spending to profitably grow production and funds flow through operational execution and maintaining prudent and conservative financial discipline.

About WesternZagros Resources Ltd.

WesternZagros is an international natural resources company focused on acquiring properties and exploring for, developing and producing crude oil and natural gas in Iraq. WesternZagros, through its wholly-owned subsidiaries, holds a 40 percent working interest in two Production Sharing Contracts with the Kurdistan Regional Government in the Kurdistan Region of Iraq. WesternZagros’s shares trade in Canada on the TSX Venture Exchange under the symbol “WZR”.

This status update contains certain forward-looking statements relating to, but not limited to, the appointment of additional directors, operational information, future development plans and the timing associated therewith. Forward-looking information typically contains statements with words such as “anticipate”, “estimate”, “expect”, “potential”, “could”, or similar words suggesting future outcomes. The Company cautions readers and prospective investors in the Company’s securities to not place undue reliance on forward-looking information as, by its nature, it is based on current expectations regarding future events that involve a number of assumptions, inherent risks and uncertainties, which could cause actual results to differ materially from those anticipated by WesternZagros.

Forward looking information is not based on historical facts but rather on management’s current expectations as well as assumptions made by, and information currently available to management, concerning, among other things, outcomes of future well operations, plans for and results of extended well tests and drilling activity, future capital and other expenditures (including the amount, nature and sources of funding thereof), the continued ability to sell production in the domestic market and the prices to be received in connection therewith, anticipated operating costs, future economic conditions, future currency and exchange rates, continued political stability, continued security in the Kurdistan Region, timely receipt of any necessary co-venturer, government or regulatory approvals, the successful resolution of disputes, the Company’s continued ability to employ qualified staff and to obtain equipment in a timely and cost efficient manner and the participation of the Company’s co-venturers in joint activities. In addition, budgets are based upon WesternZagros’s current development plans and anticipated costs, both of which are subject to change based on, among other things, the actual outcomes of well operations and the installation and commissioning of facilities, unexpected delays, availability of future financing and changes in market conditions. Although the Company believes the expectations and assumptions reflected in such forward-looking information are reasonable, they may prove to be incorrect. Forward-looking information involves significant known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those anticipated by WesternZagros including, but not limited to, risks associated with the oil and gas industry (e.g. operational risks in development and production; inherent uncertainties in interpreting geological data; changes in plans with respect to capital expenditures; interruptions in operations together with any associated insurance proceedings; the uncertainty of estimates and projections in relation to costs and expenses and health, safety and environmental risks), the risk of commodity price and foreign exchange rate fluctuations, risks relating to domestic refining capacity and continuing ability to access the domestic market, the uncertainty associated with any dispute resolution proceedings, the uncertainty associated with negotiating with foreign governments and risk associated with international activity, including the lack of federal petroleum legislation and ongoing political disputes and recent terrorist activities in Iraq in particular. For further information on WesternZagros and the risks associated with its business, please see the Company’s Annual Information Form dated March 16, 2015 (“AIF”) which is available on SEDAR at www.sedar.com.
Tony Kraljic
Senior VP Finance
+1 403 693 7011

Lisa Harriman
Manager of Investor Relations
+1 403 693 7017

Email: investorrelations@westernzagros.com

Website: www.westernzagros.com

Scorpio Gold Corp. {TSX-V: SGN}  have reported a further solid set of drill results from their 2015 expansion program at Brodie, Mineral Ridge, Nevada.

Once again good grades were encountered, with 80% of holes encountering “significant mineralisation”, close to surface.

Comment

Scorpio continue to maintain a high run rate of news releases, practically one per week, and again they didn’t disappoint with some good grades, and at shallow depths.

Oxidised ore close to surface is the miner’s dream, nice and easy to extract and process, and low costs too!

Scorpio must have the busiest IR Department on the Venture Exchange with the amount of news releases they issue!

Vancouver, August 4, 2015 – Scorpio Gold Corp. {TSX-V: SGN}  reports initial results from its 2015 expansion drilling in the Brodie deposit target area at its 70% owned Mineral Ridge project, located in Nevada.

The 2015 expansion program at Mineral Ridge includes infill, development and exploration drilling to expand and upgrade the current mineral reserve and resource base and potentially extend life of mine.

The majority of holes presented in Table 1 are step out holes collared 50-125 meters west of the 2014 floated cone pit outlines for the Brodie deposit. Over 80% of the holes intersected significant mineralisation.

Two holes of particular interest, MR151546-547, targeted a mag tilt high that corresponds with an interpreted synform axis located 125 meters west of currently defined resources for the Brodie deposit. Both holes intersected significant grades at approximately 60 meters vertical depth. Management believes that results received to date from the current expansion drilling program should positively impact the existing resource base at the Brodie deposit.

Highlights from this phase of expansion drilling on the Brodie deposit include:

• MR151492: 2.56 grams per tonne (“g/t”) gold over 7.62 meters
• MR151498: 4.08 g/t gold over 4.57 meters
• MR151528: 1.15 g/t gold over 7.62 meters
• MR151546: 6.19 g/t gold over 3.05 meters
• MR151547: 10.11 g/t gold over 1.52 meters

In addition to the step-out holes noted above, 15 exploration holes were drilled to test a broad area 150-500 meters west of the Brodie deposit. Grades of interest were reported in 4 holes (MR151502-503 and MR151544-545; Table 1) that were collared 150-200 meters west of the floated cone outlines. Three additional exploration holes (MR151548-550) that tested an area 200-250 south of the Brodie deposit did not return any significant results.

A drill hole location map is available at: www.scorpiogold.com

Table 1. Brodie Deposit Target Area – Significant Drill Results

All holes presented in Table 1 were completed by reverse circulation (RC) drilling. True width is estimated at 90-100% of downhole width. Analytical results were performed by American Assay Laboratory Inc. in Sparks, Nevada, an ISO/IEC 17025:2005 accredited facility. External check assays to verify lab accuracy are routinely completed by ALS Chemex, an ISO 9001:2000 certified and ISO/IEC 17025:2005 accredited facility. Further details are presented in the Company’s quality assurance and quality control program for the Mineral Ridge project available at: MR QAQC.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%), and Scorpio Gold is currently entitled to receive 80% of cash flow generated. Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility.

Scorpio Gold’s President & CEO, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
President & CEO

For further information contact:
Peter J. Hawley, CEO
Tel          : +1 819 825 7618
Email      : phawley@scorpiogold.com

Website  : www.scorpiogold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur, and include, without limitation, statements regarding the Company’s plans with respect to the exploration, development and exploitation of its Mineral Ridge project, including potential further exploration or development of the Brodie deposit, any potential expansion of the current pit shell outline thereof, and any potential increase in the mineral reserve and resource estimate in respect thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mineral exploration and development programs and those risk factors outlined in the Company’s Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

Copyright © 2012 SCORPIO GOLD CORPORATION (TSX: SGN) All rights reserved.

For more information;

visit our website at http://www.scorpiogold.com/

or send email to scorpio@scorpiogold.com

Inovio Pharmaceuticals Inc. {NASDAQ: INO} announced that their DNA-based monoclonal antibody proved effective by providing protection when against Dengue Fever when used in mice.

A 100% survival rate was recorded in the mice tested.

 Inovio Pharma’ DNA-Based monoclonal antibody protects mice against dengue fever.

PLYMOUTH MEETING, Pa., July 29, 2015 – Inovio Pharmaceuticals Inc. {NASDAQ: INO} announced that its DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice. A paper, “Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy,” was published in Scientific Reports, a Nature Publishing Group journal. While conventional vaccine and monoclonal antibody technologies have shown limited ability to provide an effective solution to dengue to date, the unique attributes and data generated by dMAbs show their potential to provide a needed solution.

In this study, a single intramuscular injection of a DNA plasmid encoding a monoclonal antibody targeting dengue protected mice subsequently exposed to the dengue virus. The protection conferred by the monoclonal antibodies expressed by these dMAbs was very rapid, with 100% survival in mice challenged with lethal enhanced dengue disease less than a week after dMAb administration – this short time frame to achieve full protection is significantly more rapid than vaccine-driven protection, which can take weeks to months to reach peak efficacy levels.

“This is a positive step on the path to show the broad potential of our novel dMAbs to provide rapid onset of powerful protective and therapeutic capabilities,” said Dr. J. Joseph Kim, President and CEO of Inovio. “This is the first study to report on our dMAb product’s ability to generate fully functional monoclonal antibodies in vivo and provide protection against a lethal viral challenge.

“This is just the beginning. We are building a comprehensive dMAb technology development program that includes immuno-oncology products as well as infectious disease dMAb products, with significant funding already awarded by DARPA to enable our development of dMAb based products against influenza, antibiotic-resistant bacteria, and Ebola.”

Unlike conventional monoclonal technology, which involves constructing protein-based antibodies and manufacturing them in cell culture in a complex and costly process, Inovio’s patent-protected dMAb technology encodes the DNA sequence for a specific monoclonal antibody in a highly optimized plasmid, which would be delivered directly into a subject’s arm using electroporation. Cells in the body would then produce the encoded monoclonal antibody molecules, with intended functional activity including high antigen-binding and neutralization capabilities against the targeted disease. Monoclonal antibodies offer the benefit of inducing a rapid onset of the immune response. DNA-based monoclonal antibody technology provides significant advantages over conventional monoclonal antibody technology, including faster development, easier product manufacturing, and more favorable pharmacokinetics. The current monoclonal antibody product market is well over $50 billion.

 
About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases.

Their immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Gene One Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, EORTC, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended March 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACT: Inovio:

Investors:
Bernie Hertel
Inovio Pharmaceuticals
+1 858-410-3101
bhertel@inovio.com

Scorpio Gold Corporation  {TSX-V: SGN} continues to produce news releases at a rapid rate, and again the news is good for shareholders.

They have managed to negotiate a superior finance package than that previously agreed, and the board have decided to move forwards with this one, initiating the break clause in the previous agreement.

Scorpio Gold Enters into Term Sheet for Non-Dilutive Debt Financing with Waterton and Provides Corporate Update

Inovio Pharmaceuticals. {NASDAQ: INO}  today announced they are “taking  immunotherapy to the next level” by initiating a phase 1 trial for men with relapsed prostrate cancer.

This follows the success of trials using INO-5150 on non human primates.

PLYMOUTH MEETING, Pa., July 27, 2015 – Inovio Pharmaceuticals. {NASDAQ: INO} announced today that it has initiated a phase I trial to evaluate Inovio’s DNA immunotherapy in men with biochemically relapsed prostate cancer.

The launch of this human trial follows strong pre-clinical results revealing that INO-5150 generated robust CD8⁺ T cell responses in animal studies including non-human primates. The immune responses generated by INO-5150 were similar in character to immune responses generated by VGX-3100, Inovio’s immunotherapy for human papillomavirus (HPV) that regressed pre-cancerous cervical lesions and eliminated HPV in a randomized, placebo-controlled phase II trial.

INO-5150 is a novel SynCon^® immunotherapy for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA), present in the majority of prostate cancer cells. This phase I study will evaluate the safety, tolerability, and immunogenicity of INO-5150 alone or in combination with INO-9012, Inovio’s DNA-based IL-12 immune activator. The multi-centered study will also evaluate changes in PSA levels, an important biomarker in prostate cancer.

INO-5150 was generated using Inovio’s proprietary SynCon^® process to enable significant production of PSA and PSMA antigens with genetic sequences differentiated from native human PSA and PSMA sequences. This patented approach is designed to help the body’s immune system overcome its “self-tolerance” to prostate cancer cells and mount a strong targeted CD8⁺ killer T cell response to eliminate the cancerous cells displaying these antigens.

Dr. J. Joseph Kim, President and CEO, said, “Inovio is focused on taking immunotherapy to the next level. Inovio is the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes. With positive results from our phase II study of VGX-3100, Inovio’s active immunotherapy technology is a promising approach to treat various solid tumors by targeting the most important antigens for a particular tumor. Today’s launch of our SynCon^® prostate cancer immunotherapy builds on Inovio’s current trials for several difficult-to-treat cancers including head and neck, cervical, breast, lung, and pancreatic cancer.”

About Prostate Cancer

Prostate cancer is the second most frequently diagnosed cancer in men. Nearly three-quarters of the registered cases occur in developed countries. Accounting for nearly 300,000 deaths each year, prostate cancer is the sixth leading cause of death from cancer in men. The development of a new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and are often not a long-term cure.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, EORTC, DARPA, Gene One Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information:   www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended March 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACT:
Inovio:
Investors: Bernie Hertel,
Inovio Pharmaceuticals,
+1 858-410-3101,

Barkerville Gold Mines Ltd. {TSX.V: BGM}  today announced the first drill results from the BC Vein drill program.

The highlights include 22.03 gpt over 7.7 metres, and 24.66 gpt over 8 metres.

BGM Announces First Drilling Results from Phase I Program on BC Vein and Closing of Flow-Through Unit Offering

VANCOUVER, BC– July 28, 2015 – Barkerville Gold Mines Ltd. {TSXV: BGM} announced the first of its Phase I drilling results on the BC Vein located on Barkerville Mountain at the Company’s flagship Cariboo Gold Project. As part of due diligence, drillholes BGM-15-001 through BGM-15-004 were designed to validate the historical drillhole database by confirming the gold grades and geometry of the BC Vein.

Drillhole cross sections as well as a location plan map are located on the Company’s website www.barkervillegold.com.

Highlights:

22.03 g/t (0.64 oz/t) Au over 7.70 metres, including 109.84 g/t (3.20 oz/t) Au over 1.00 metres
24.66 g/t (0.72 oz/t) Au over 8.00 metres, including 127.68 g/t (3.72 oz/t) Au over 1.00 metres

Full result table is available at   www.barkervillegold.com

Notes:

Core lengths represent 70-90% true widths. Rock not recovered by drilling was assigned zero grade and not included in the composites. Top cuts have not been applied to high grade assays. 1.0 ounces = 34.285 grams. BCV – BC Vein; HWV – Hanging Wall Vein.

Discussion of Results

Designed as validation drillholes to confirm both historical gold grades and the BC Vein geometry, drillholes BGM-15-001 through BGM-15-004 were successful in positively correlating previous operators drilling programs and hence confirming the existing drillhole database. In addition to successfully  validating the BC Vein, gold bearing hanging wall veins, were also intersected by holes BGM-15-002 and BGM-15-003 (Table 1 on the webisite).

With due diligence now complete, drilling will be focused on targets northeast of the Bonanza Ledge open pit, the BC Vein as well as previously untested soil and bedrock gold anomalies on Barkerville Mountain with the ultimate goal of drill defining mineable gold resources.

Commentary

Tom Obradovich, President and CEO of the Company comments: “I am pleased that our technical team in conjunction with our structural consultants have  developed an understanding of the mineralisation targeted in this program. New targets have been developed and we are excited given the high grade nature of the vein systems the team has identified.”

Closing of Flow Through Unit Offering

The Company is also pleased to announce that further to its press release of July 15, 2015, it has completed a private placement of 9,375,000 flow through units (the “Flow Through Units”) at a price of $0.32 per Flow Through Unit for gross proceeds of $3,000,000 (the “FT Offering”). Each Flow Through Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”) with each Warrant entitling the holder thereof to purchase a common share at an exercise price of $0.40 until January 23, 2017.

The Company intends to use the net proceeds from the FT Offering to explore Cariboo Gold Project and related properties in British Columbia. The securities issued pursuant to the FT Offering are subject to a four month hold period until November 24, 2015.

Qualified Persons

Exploration activities at the Cariboo Gold Project are jointly administered on site by the Company’s Project Managers Maggie Layman, P.Geo. and Wanda Carter, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.
Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company’s secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by
Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to SGS Canada’s analytical facility in Burnaby, B.C. for preparation and analysis. The SGS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 1,000 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 5ppb and upper limit of 10,000ppb. Samples with gold assays greater than 10,000ppb are re-analyzed using 50g fire assay with gravimetric finish, as well as 1,000g screen metallic fire assay. Samples are also analyzed using a 49 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

For further information on BGM Ltd., please contact:

Tom Obradovich

President & Chief Executive Officer

+1 416 361 2511

tobradovich@sympatico.ca

About BGM

The company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. BGM’s mineral tenures cover 1,164 square kilometres along a strike length of 60 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by BGM in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of this year with 91,489 tonnes of ore milled producing 25,464 ounces of gold. BGM has completed a number of drilling and exploration programs over the past 20 years and is currently compiling this data with all historical information in order develop geologic models which will assist new management and provide the framework to continue to explore the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange (“TSX.V”) nor its Regulation Services Provider (as that term is defined in the policies of the TSX.V) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Scorpio Gold Corp. {TSX.V: SGN} have reported further positive drill results form their satellite NW Brodie at Mineral Park, Nevada.

This is part of the 2015 expansion campaign at Mineral Park.

Nymox Pharmaceuticals (NASDAQ: NYMX} shares doubled in a day upon the news that their phase 3 extension trial for NX-1207 was successful.

Nymox, whose shareprice was decimated with a prior disappointing result, now appears to be in the ascendancy again on the release of this excellent news.

For Immediate Release:

Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207).

HASBROUCK HEIGHTS, NJ (July 27, 2015) Nymox Pharmaceutical Corp. {NASDAQ: NYMX} announced today that the Company’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).

The Company now intends to meet with authorities and to proceed to file where possible in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories.

The primary endpoint variable of the long-term study was improvement in the AUA BPH Symptom Score which was statistically significant (p<.02) in fexapotide-treated patients compared to placebo, at a median duration of 42 months (3.5 years) after a single double-blind injection treatment of fexapotide vs. saline placebo. In addition, responder analysis for the primary endpoint variable met the prespecified endpoint (p<.01). All subjects from both studies with 2 years or more duration follow-up after a single painless injection were eligible, however all documented treatment failures of any duration in the studies from day 1 onward were also included in the data as treatment failures. Patients were followed double-blind up to 65 months (5.4 years) after a single injection.

Highlights of the pivotal Phase 3 extension top-line results are summarized as follows:

• Median duration of 3.5 years from a single injection treatment mean improvement of 5.3 points in AUA BPH Symptom Score. Statistically significant (mean p<.025; median p<.02) vs saline placebo injection.

•  Mean improvement of 7.1 points in AUA BPH Symptom Score (primary endpoint variable) after median duration of 3.5 years in first-line BPH treatment of fexapotide treated subjects (p<.025 vs placebo).

•  Patient responder rate: Statistically significant higher proportion (64%) of long-term improved patients in AUA BPH Symptom Score (primary outcome variable) after a single injection in fexapotide treated subjects vs controls (p<.005).

• Improvement of nocturia: Percentage of patients with stabilization or improvement of frequency of nocturia in fexapotide treatment superior to placebo (p<.03).

The Company also reported on new Phase 3 data of lowered incidence of surgery in patients in Phase 3 studies NX02-0020 and NX02-0022.

 Reduced incidence of surgery: Subjects in Phase 3 studies NX02-0020 and NX02-0022 with 1 or 2 injections of fexapotide had statistically significant reduction of BPH surgery within 24 months of fexapotide treatment (1.7% incidence of surgery in 2 years) (p<.02 vs placebo).

In addition, the following advantages of the new drug are highlighted:

•  Safety profile highly superior to existing treatments. Minimal or no sexual, hormonal or cardiovascular or other debilitating side effects.

• Reduced cancer risk in Phase 2 data: U.S. Phase 2 data showing therapeutic effect of fexapotide on prostate cancer. Phase 2 data showed fexapotide treated low grade localized prostate cancer (Gleason 3+3 or less) had statistically significant less progression compared to controls. By comparison, some commonly used older approved BPH treatments have been linked to increased cancer risk.

• Enhanced compliance and patient convenience compared to oral medications. Fexapotide is given as a single painless office treatment injectable. Older approved oral medications generally involve daily pills intended for the rest of the patient’s life.

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH, the potential of NX-1207 to treat BPH and the estimated timing of further developments for NX-1207. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on NX-1207, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of NX-1207. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.

Inovio Pharma {NASDAQ: INO} announced a collaboration with the EORTC to evaluate Inovio’s immunotherapy INO-3112 in respect of cervical cancer treatment.

Dr. J. Joseph Kim, President and CEO, said, “Inovio is focused on taking immunotherapy to the next level”

PLYMOUTH MEETING, Pa., July 23, 2015  Inovio Pharmaceuticals Inc. {NASDAQ: INO} announced today that it is collaborating with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate Inovio’s immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer.

The trial, primarily funded by the EORTC, is expected to begin by the end of the year.

Partnership with the EORTC will offer Inovio clinical trial efficiency and speed in recruiting patients in Europe and in obtaining and analyzing results. The EORTC encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses. EORTC is the only organisation which carries out clinical studies throughout Europe for all types of cancer. Collaboration with the EORTC also leverages their connections to a network of more than 2,500 pre-clinical scientists and oncologists in more than 300 hospitals in over 30 countries.

Dr. J. Joseph Kim, President and CEO, said, “Inovio is focused on taking immunotherapy to the next level. We are the only immunotherapy company that is generating, in vivo, T cells in high quantity that are fully functional and which have demonstrated killing capability correlated with relevant clinical outcomes. We are very pleased that Inovio’s approach attracted the attention of a premier cancer organization like the EORTC to sponsor this important study in women with cervical cancer.”

INO-3112 consists of Inovio’s HPV 16 and 18 immunotherapy (VGX-3100) and its IL-12-based immune activator (INO-9012). In this prospective, randomized, three arm phase II study, INO-3112 will be administered during standard chemo-radiotherapy (CRT) or during and after standard CRT as an adjuvant in patients with locally advanced cervical cancer. The primary endpoint is to demonstrate sufficient activity in the experimental combination arms to warrant a further pivotal phase III trial based on progression free survival (PFS) at 18 months. Efficacy will be assessed within each experimental arm while the standard arm will serve as a reference arm to check the reliability of the results. PFS at 18 months will be determined  via RECIST criteria as assessed by the local investigator. The co-primary investigators are Georges Coukos, M.D. and  Fernanda G. Herrera, M.D., both of whom are with the Centre Hospitalier Universitaire Vaudois  in Lausanne, Switzerland.

Secondary endpoints include overall survival, clinical response, immunogenicity, tolerability and safety.

This international study will enroll patients in several European countries and will complement and build on an Inovio-sponsored study already underway at several centers in the United States (Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation in Women with Cervical Cancer after Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease).

The efficacy and immunogenicity of VGX-3100, the basis of INO-3112, in patients with the precursor to cervical cancer (high grade cervical dysplasia) has already been demonstrated in a large, prospective, randomized, double blind, placebo-controlled phase II study, HPV-003. Treatment with VGX-3100 resulted in histopathological regression of high grade cervical dysplasia to low grade or no disease, meeting the study’s primary endpoint. In addition, the trial demonstrated clearance of the HPV virus in conjunction with regression of cervical lesions, meeting the secondary endpoint. Robust T-cell activity was observed in subjects who received VGX-3100 compared to those who received placebo.

About the EORTC

The EORTC is a vibrant example of the fact that academic science and research know no national boundaries. Established in 1962, the EORTC is a non-profit European research organization operating as an international association under Belgian law. The EORTC currently links a network of more than 2,500 pre-clinical scientists and oncologists in more than 300 hospitals in over 30 countries. It encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses. The 170 members of the EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. The ultimate goal of the EORTC is to improve the future of cancer therapy by developing new agents and innovative approaches and to test more effective treatment strategies using commercially available drugs, or surgery and radiotherapy. For more information, visit www.eortc.org

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Gene One Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, EORTC, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon(R) active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended March 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Investors:
Bernie Hertel, Inovio Pharmaceuticals,
858-410-3101, bhertel@inovio.com

Range Energy Resources {CSE: RGO} have announced two boardroom changes, with one new member replacing an outgoing one.

Range welcome newcomer Eric Stoerr, an experienced investment professional, formerly a director of WesternZagros.

Range Energy Resources appoints Stoerr to board

Mr. Toufic Chahine reports.

CORPORATE UPDATE

Range Energy Resources Inc. {CSE: RGO} has appointed Eric Stoerr as a director of the company. Mr. Stoerr is an investment professional at Crest Investment Company.

Mr. Stoerr has more than 19 years of experience in commodities-related businesses and banking, including investment and commercial banking, commodity trading, and business development. Prior to managing Crest’s investments in energy and natural resources, he served as managing director at Royal Bank of Scotland, North American energy finance group.

He served as a director of WesternZagros Resources Ltd. from August, 2012, to Feb. 19, 2014. Mr. Stoerr holds a BSc in business administration from Skidmore College, Saratoga Springs, N.Y., and a master in business administration from Tulane University, New Orleans, La.

The company has accepted the resignation of Pamela Powers as a director, effective July 17, 2015. The board of directors wishes to express its gratitude to Ms. Powers for her contributions to the company and to wish her well with her future endeavours.

We seek Safe Harbor.

Cartier Resources Inc. {TSX.V: ECR} confirm positive geophysical test results on their Cadillac Extension project in the Abitibi Greenstone belt, Quebec.

These results have also detected three new anomalies.

CARTIER RESOURCES INC.: POSITIVE GEOPHYSICAL TEST RESULTS ON CADILLAC EXTENSION

Cartier Resources Inc. {TSX.V: ECR} has received positive geophysical test results on the Cadillac extension project, situated 135 kilometers east-northeast of Val d’Or. The results of the OreVision technology calibration test line, completed over the poly-metallic copper-zinc-silver (Cu-Zn-Ag) Langlade deposit, has helped outline the geometry and position of the favourable horizon that hosts the mineralisation. These results have also detected three new anomalies, associated with sulphides, of which one is situated along the extension of the Langlade deposit.

The OreVision technology measures resistivity and chargeability of the rocks down to a depth of 600 mettrs. These results, when compared with results obtained from the laboratory characterization of the host rocks and the mineralisation targeted on the property, help locate with good precision the position of anomalies associated with sulphides present on the property. The robust nature of the targets is supported by the magnetic signature and diamond drill hole data.

Philippe Cloutier, president and chief executive officer, commented: “Now that we have calibrated the instruments to detect what we are looking for, we are planning surveys over parts of the property with a high potential for discovery of deposits.”

For more information on the Cadillac extension project visit the company’s website.

Quality assurance/quality control

The scientific and/or technical information presented in this press release has been reviewed and approved by Dr. Gaetan Lavalliere, PGeo, PhD, and vice-president for Cartier. Mr. Lavalliere is a qualified person as defined by National Instrument 43-101.